Imatinib
Refractory Pediatric Solid Tumor
Samsung Medical CenterSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Refractory Pediatric Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Malika Kapadia | Phase 2 | BB |
gw786034 Samsung Medical Center | Phase 2 | B |
Ifosfamide Samsung Medical Center | Phase 2 | B |
Carboplatin Samsung Medical Center | Phase 2 | B |
Ipilimumab Children's National Research Institute | Phase 2 | B |
View all 14 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →